---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-028809"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:25:39.367233+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Dr. Joyce transfers Village Oaks Pathology equity to Dr. Humphreys; new succession agreement executed

## Summary
- Dr. Joyce (77) informed Company of desire to transfer 100% stock of Village Oaks Pathology to Dr. Humphreys; not due to disagreement.
- On Dec 22, 2025, Village Oaks Pathology, PPLS, and Dr. Humphreys entered a Succession Agreement restricting disposal of equity.
- Agreement provides for automatic transfer of equity to a successor upon death, disability, retirement, incompetence, or failure to meet eligibility requirements.
- Dr. Humphreys must use commercially reasonable efforts to preserve Village Oaks Pathology's operations, contracts, and licenses.

## SEC filing metadata
- accession: 0001493152-25-028809
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315225028809/0001493152-25-028809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315225028809/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-028809
- JSON: https://secwatch.observer/filing/0001493152-25-028809.json
- Plain text: https://secwatch.observer/filing/0001493152-25-028809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.